Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy
October 27 2021 - 7:45AM
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the
“Company”), a novel biotechnology company focused on the research
and discovery of new and effective treatments for psychiatric and
neurological disorders, today announced that Pasithea Clinics, its
wholly owned subsidiary, has administered intravenous (“IV”)
ketamine therapy to its first patients. In sub-anesthetic doses,
ketamine has shown to be highly effective at treating some
psychiatric disorders, such as treatment-resistant depression and
post-traumatic stress disorder.
“With major depression the leading cause of
long-term disability worldwide and mental health cases on the rise,
new therapies are urgently needed for patients who do not respond
to traditional treatments. Today, we are thrilled to announce that
we administered our first IV ketamine infusion therapy to patients
with treatment-resistant depression,” stated Dr. Tiago Reis
Marques, CEO of Pasithea Therapeutics.
“This is a significant milestone for Pasithea
Clinics and for patients in the U.K. suffering with mental health
conditions. Decades of evidence supports the efficacy of ketamine
in improving symptoms for some mental health disorders, and studies
have shown that up to 70% of those who receive IV ketamine
treatment will eventually show a clinical response. We are excited
to continue providing treatment to patients deemed eligible to
receive it,” concluded Dr. Reis Marques.
Ketamine is a U.S. Food and Drug Administration
(“FDA”) approved drug introduced as an anesthetic more than 50
years ago. It has recently been repurposed in significantly lower
doses for the treatment of psychiatric disorders and is now gaining
ground as a promising treatment for mental health disorders. In
certain psychiatric conditions, such as treatment-resistant
depression (“TRD”) and post-traumatic stress disorder (“PTSD”), it
has shown remarkable efficacy and a rapid and sustained effect.
Pasithea has clinical partnerships to administer
its IV ketamine treatment. In the U.K., it has partnered with ZEN
Healthcare – a network of health clinics in London. In the U.S., it
has partnered with The IV Doc, Inc. to provide in-home IV ketamine
infusions. Both partnerships offer rapid exposure and expansion
opportunities.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corporation is a U.S.
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders. With an experienced team of experts in the fields of
neuroscience and psychopharmacology, Pasithea is developing new
molecular entities for the treatment of psychiatric and
neurological disorders. Pasithea is also focused on addressing the
needs of patients currently suffering with mental illness by
providing access to IV ketamine infusions both in clinics and
in-home settings.
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements.” Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company ContactDr.
Tiago Reis MarquesChief Executive OfficerE: tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
RelationsLisa M. WilsonIn-Site Communications, Inc.T:
212-452-2793E: lwilson@insitecony.com
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Sep 2023 to Sep 2024